Evidence map›Paper›PMID 33851198›Full record

ArticleThe Journal of nutrition2021

Cholecalciferol Supplementation Does Not Prevent the Development of Metabolic Syndrome or Enhance the Beneficial Effects of Omega-3 Fatty Acids in Obese Mice.

Marion Valle, Patricia L Mitchell, Geneviève Pilon, Philippe St-Pierre, Thibault Varin, Denis Richard, Marie-Claude Vohl, Hélène Jacques, Edgar Delvin, Emile Levy and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of nutrition, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Marion ValleQuébec Heart and Lung Institute Research Centre, Faculty of Medicine, Laval University, Québec City, QC, Canada.
Patricia L MitchellQuébec Heart and Lung Institute Research Centre, Faculty of Medicine, Laval University, Québec City, QC, Canada.
Geneviève PilonQuébec Heart and Lung Institute Research Centre, Faculty of Medicine, Laval University, Québec City, QC, Canada.
Philippe St-PierreQuébec Heart and Lung Institute Research Centre, Faculty of Medicine, Laval University, Québec City, QC, Canada.
Thibault VarinQuébec Heart and Lung Institute Research Centre, Faculty of Medicine, Laval University, Québec City, QC, Canada.
Denis RichardQuébec Heart and Lung Institute Research Centre, Faculty of Medicine, Laval University, Québec City, QC, Canada.
Marie-Claude VohlInstitute of Nutrition and Functional Foods, Laval University, Québec City, QC, Canada.
Hélène JacquesInstitute of Nutrition and Functional Foods, Laval University, Québec City, QC, Canada.
Edgar DelvinDepartment of Nutrition and Biochemistry, Sainte Justine Hospital Research Centre, University of Montreal, Montreal, QC, Canada.
Emile LevyInstitute of Nutrition and Functional Foods, Laval University, Québec City, QC, Canada.
Claudia GagnonQuébec Heart and Lung Institute Research Centre, Faculty of Medicine, Laval University, Québec City, QC, Canada.ORCID 0000-0001-9623-962X
Laurent BazinetInstitute of Nutrition and Functional Foods, Laval University, Québec City, QC, Canada.
André MaretteQuébec Heart and Lung Institute Research Centre, Faculty of Medicine, Laval University, Québec City, QC, Canada.
Université Laval · CACentre Hospitalier Universitaire Sainte-Justine · CACentre hospitalier universitaire de Québec · CA

Funding

CIHR FH4-129922
6 · The paper itself

Abstract

backgroundCholecalciferol (D3) may improve inflammation, and thus provide protection from cardiometabolic diseases (CMD), although controversy remains. Omega-3 fatty acids (ω-3FA) may also prevent the development of CMD, but the combined effects of ω-3FA and D3 are not fully understood.

objectivesWe determined the chronic independent and combined effects of D3 and ω-3FA on body weight, glucose homeostasis, and markers of inflammation in obese mice.

methodsWe gave 8-week-old male C57BL/6J mice, which had been fed a high-fat, high-sucrose (HF) diet (65.5% kcal fat, 19.8% kcal carbohydrate, and 14% kcal protein) for 12 weeks, either a standard D3 dose (+SD3; 1400 IU D3/kg diet) or a high D3 dose (+HD3; 15,000 IU D3/kg diet). We fed 1 +SD3 group and 1 +HD3 group with 4.36% (w/w) fish oil (+ω-3FA; 44% eicosapentaenoic acid, 25% docosahexaenoic acid), and fed the other 2 groups with corn oil [+omega-6 fatty acids (ω-6FA)]. A fifth group was fed a low-fat (LF; 15.5% kcal) diet. LF and HF+ω-6+SD3 differences were tested by a Student's t-test and HF treatment differences were tested by a 2-way ANOVA.

resultsD3 supplementation in the +HD3 groups did not significantly increase plasma total 25-hydroxyvitamin D and 25-hydroxyvitamin D3 [25(OH)D3] versus the +SD3 groups, but it increased 3-epi-25-hydroxyvitamin D3 levels by 3.4 ng/mL in the HF+ω-6+HD3 group and 4.0 ng/mL in the HF+ω-3+HD3 group, representing 30% and 70%, respectively, of the total 25(OH)D3 increase. Energy expenditure increased in those mice fed diets +ω-3FA, by 3.9% in the HF+ω-3+SD3 group and 7.4% in the HF+ω-3+HD3 group, but it did not translate into lower body weight. The glucose tolerance curves of the HF+ω-3+SD3 and HF+ω-3+HD3 groups were improved by 11% and 17%, respectively, as compared to the respective +ω-6FA groups. D3 supplementation, within the ω-3FA groups, altered the gut microbiota by increasing the abundance of S24-7 and Lachnospiraceae taxa compared to the standard dose, while within the ω-6FA groups, D3 supplementation did not modulate specific taxa.

conclusionsOverall, D3 supplementation does not prevent CMD or enhance the beneficial effects of ω-3FA in vitamin D-sufficient obese mice.

Indexed as

AnimalsCholecalciferolDietary SucroseDietary SupplementsDiet, High-FatDrug SynergismFatty Acids, Omega-3Glucose IntoleranceHumansLeptinLiverMaleMetabolic SyndromeMiceMice, Inbred C57BLMice, ObeseCholecalciferolDietary SucroseFatty Acids, Omega-3Leptinfish oilglucose toleranceliver metabolismmetabolic syndromevitamin D

Identifiers

PMID33851198
PMCPMC8112766
OpenAlexW3154938533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.